Marker Therapeutics, Inc.
MRKR· Nasdaq
MRKRMarker Therapeutics, Inc.
Filed May 11, 2020 · 10-Q · 41 days after period end · 0001104659-20-059515
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Net Income | -$6.49M | -$5.32M | -$3.20M | -$2.42M |
| EPS Diluted | -$0.14 | -$0.12 | -$0.30 | -$0.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
ended Mar 31, 2020 · filed May 11, 2020 · 41 d after period end
